Progressive osseous heteroplasia in a 5-year-old boy with a novel mutation in exon 2 of GNAS: a case presentation and literature review
BMC Musculoskeletal Disorders volume 24, Article number: 247 (2023)
Progressive osseous heteroplasia (POH) is a rare genetic condition that causes progressive ossification. This usually results from an inactivating mutation of the paternal GNAS gene. Herein, we report a case of POH caused by a novel mutation in exon 2 of the GNAS gene.
A 5-year-old Chinese boy was referred to our hospital for a growing mass in his right foot. Although laboratory findings were normal, radiographic imaging revealed severe ossification in his right foot and smaller areas of intramuscular ossification in his arms and legs. A de novo mutation (c.175C > T, p.Q59X) in exon 2 of the GNAS gene was identified, prompting a diagnosis of POH. We conducted a systematic literature review to better understand this rare disease.
We have discovered that a de novo nonsense mutation in exon 2 of GNAS can lead to POH. Our literature review revealed that ankylosis of the extremities is the primary clinical outcome in patients with POH. Unlike other conditions such as fibrodysplasia ossificans progressiva (FOP), patients with POH do not experience respiratory failure. However, much remains to be learned about the relationship between the type of GNAS gene mutation and the resulting POH symptoms. Further research is needed to understand this complex and rare disease. This case adds to our current understanding of POH and will contribute to future studies and treatments.
Progressive osseous heteroplasia (POH) is an extremely rare genetic disorder characterised by progressive formation of heterotopic ossification in deep connective tissues and skeletal muscles . POH’s severity can range from subcutaneous lesions to complete ankylosis of the involved joints [2, 3]. It is primarily caused by inactivating mutations of the paternal GNAS gene. The GNAS gene is located on chromosome 20q13.3 and encodes the alpha subunit of the stimulatory G protein (Gsα) and other imprinted transcripts [2, 4, 5]. Heterozygous inactivating mutations of GNAS are also responsible for Albright’s hereditary osteodystrophy (AHO) , which includes a constellation of symptoms: brachydactyly, stocky build, short stature, round face ectopic ossification, and intellectual disability [6, 7]. In POH and AHO, heterotopic ossification primarily occurs via intramembranous ossification . Overlapping syndromes, such as POH/PHP1A and POH/PPHP, have also been reported [8,9,10,11]. POH and AHO are considered as part of the same spectrum of GNAS-related ossification diseases. However, compared to AHO, POH is considered a more severe form of the disease as it is associated with greater ossification.
Since its initial description in 1994 , apart from one large cohort , only a few individual cases and case series have been published worldwide. This has limited our ability to better understand this rare disease. Herein, we present a case of POH with a novel mutation in exon 2 of GNAS.
On April 02, 2021, a 5-year-old Chinese boy visited our hospital with complains of a progressively growing mass under the skin of his right foot for 1 year. The boy was born at full-term after an uncomplicated pregnancy with a birth weight of 2.8 kg. At 4 years of age, his parents noticed a hard mass under his right foot, with no signs of redness or swelling over the skin. The family visited a local hospital, where radiographs revealed ossification of the right foot. Further investigations were recommended, however, the patient’s parents refused and requested only observation at the time. Over the following year, the mass grew, however, it was manageable during mechanical loading. The boy was healthy prior to this.
Physical examination at our hospital revealed that the boy was 102.5 cm tall (-2 SD) and weighed 14.5 kg (-2 SD). He was a slim, right-handed boy with Tanner I pubertal development and no signs of mental retardation or developmental delay. A comprehensive subcutaneous mass was palpable in sole of the right foot, which extended to the Achilles tendon and caused minimal limitations in ankle movement. The mass could not be precisely localised. The remainder of the physical examination results were normal.
The serum levels of calcium, phosphorus, and alkaline phosphates were found to be normal. An anteroposterior radiograph of the right foot showed long sheets of opacification across the plantar aspect of the foot and heel, some opacified sheets were continuous with metatarsals and tarsal bones (Fig. 1). Axial computed tomography (CT) images revealed ossification in the right foot between the second and third metatarsals, which was continuous with the foot bones. Three-dimensional CT revealed progression of the ectopic ossification (Fig. 1). X-ray screening was performed to identify other sites of heterotopic ossification, small areas of intramuscular ossification were observed at the superior margin of bilateral proximal humerus (Fig. 2). Additionally, a limited radio-dense lesion was noted in the right popliteal fossa (Fig. 3).
Soft-tissue ossification-causing rheumatic diseases, such asjuvenile dermatomyositis, systemic lupus erythematosus, and systemic sclerosis, were ruled out as the patient showed no systemic clinical features and tests for autoantibodies were negative. There was a high suspicion of fibrodysplasia ossificans progressiva (FOP) due to the massive heterotopic ossification. FOP was ruled out because the patient showed no signs of inflammatory soft tissue swelling or malformed great toes. The large heterogeneously ossified mass, progressive nature of the lesions, and normal laboratory findings prompted a clinical diagnosis of POH. AHO was unlikely, as the patient did not exhibit any other characteristic anomalies of AHO despite the short stature.
Whole-exome sequencing was performed to confirm the diagnosis. A de novo heterozygous inactivating mutation (c.175C > T, p. Q59X) was identified in exon 2 of the GNAS gene. This is the first reported case of such a mutation leading to POH. Physical therapy was recommended to preserve movement. The ossified lesion continued to grow slowly over the following year.
We performed a comprehensive literature search using the search string: (Progressive Osseous Heteroplasia) OR ((Heterotopic Ossification) AND GNAS)) AND ("1999/12/31"[Date—Publication]: "2022/01/01"[Date—Publication]). A total of 166 articles were retrieved from PubMed, one additional article was identified through an online search engine. After eliminating duplicates, 164 studies were included. Subsequently, 112 articles were deemed irrelevant based on the title and abstract and were excluded. Thereafter, 22 articles were excluded for various reasons (Fig. 4). Finally, 30 articles, which included 40 patients (22 female), were analyzed, the clinical and genetic features are summarized in (Additional file 1: Table 1) [3, 8, 10, 11, 14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39].
Discussion and conclusion
POH is an extremely rare genetic disorder that results in progressive heterotopic ossification. We identified a de novo mutation (c.175C > T, p.Q59X) in the GNAS gene in a young Chinese boy with typical features of POH. Although it was not determined which parental allele carried the mutation, the lack of AHO features and the presence of hormone resistance suggested that it was carried on the paternal allele.
A comprehensive literature review was conducted to gain a deeper understanding of the disease. POH commonly presents in infancy and childhood (average onset age 2.34 years), with only one patient having adult-onset ossification. Patients with POH are often diagnosed late owing to the rarity of the disease and its gradual onset. The age at onset in our patients may have been earlier than 4 years, as the ossification sites are difficult to detect. POH can be categorised as widespread heterotopic ossification with no functional impairment or progressive heterotopic ossification resulting in complete ankylosis. Our patient seemed to belong to the first category, as no severe ankylosis was found. In most patients with POH, ossification was predominantly seen in the extremities (83%, 34/41) and lower back (34%, 14/41), with only four patients (4/41, 10%) having ear and mandible involvement. Unilateral involvement was encountered in 46% (19/41) of patients and bilateral asymmetrical involvement in 64% (22/41) of the patient. Unlike FOP, none of the patient with POH suffered from dyspnoea due to respiratory muscle involvement. The predominant clinical outcome in patients with POH is ankylosis of the limbs, the trunk is not involved. One third of the patients with POH (12/41) had more than one clinical feature of AHO with or without hormonal resistance, supporting the notion that POH represents one end of the spectrum of GNAS-related diseases.
GNAS gene mutations (Fig. 5) were found in only 66% (27/41) of patient with POH, with a four-base pair deletion of c.565–568 being present in 17.10% (7/41) of the patients. This deletion “hotspot” has been reported in patients with other GNAS-related diseases, such AHO, PHP1A, and OC . The same GNAS mutation could cause both types of ossifications, with no specific distribution pattern. A unique case of POH was reported in two monochorionic twins with the same mutation and genetic background, however, the clinical presentations differed . Two patients with POH and without GNAS mutations had a family history of heterotopic ossification and/or hormone resistance [15, 16], indicating that POH is influenced by various factors in addition to genetics. Further research is needed to explore the role of unknown epigenetic modifications and environmental factors in ectopic ossification.
Currently, no medication can effectively reverse or prevent ossification associated with POH. Recurrence of lesions in POH following resection is common, and the recurrent lesions tend to be larger in size [35, 40, 41]. We recommended meticulous skin care and physical therapy . POH management is supportive, with a focus on educating patients and improving their quality of life. Recently, Qian et al.  discovered a self-amplifying, self-propagating loop of Yes-associated protein (YAP) and Sonic hedgehog (SHH) that plays a key molecular role in the development of ossification in POH. These results suggest that the inhibition of YAP or SHH could prevent, reduce, and shrink POH lesion, while maintaining normal bone homeostasis. Although a few patients have been followed-up, the long-term prognosis of POH remains uncertain. The disease stabilised or progressed at a slower rate in the patients who were followed-up . In one case reported by Ezzat El Sobky et al., a patient with POH succumbed to death due to a severe secondary infection of the skin ulcers overlying the subcutaneous ossification . Further research of the disease is required. Given the progressive nature of POH, it is essential to closely monitor affected young individuals, as their phenotype may become more complex over time.
In conclusion, POH is an extremely rare condition characterised by progressive ossification of the skin, subcutaneous tissue, and connective tissue, leading to immobility in severe cases. POH is caused by a genetic mutation, specifically an inactivating mutation of the GNAS gene located on the paternal allele. This report describes the case of a boy with typical POH symptoms and radiographic findings, in whom a de novo mutation was detected in exon 2 (c.175C > T, p.Q59X) of the GNAS gene. A systematic literature review revealed that limb ankylosis is a common outcome in patient with POH. Unlike in FOP, there have been no reports of respiratory failure in patients with POH due to ossification of respiratory muscles. Our literature review also revealed no clear relationship between the genetic mutations and the clinical manifestations. Through this report we aimed to increase awareness and understanding of this rare disorder among healthcare professionals, including physicians, paediatricians, and orthopaedic surgeons. We recommend avoiding unnecessary treatment and surgeries and providing proper counselling for patients and families.
Availability of data and materials
Data sharing does not apply to this article, as no datasets were generated or analyzed during the current study.
Progressive osseous heteroplasia
Fibrodysplasia ossificans progressive
The alpha subunit of stimulatory G protein
Pseudohypoparathyroidism type 1A
Albright’s hereditary osteodystrophy
American College of Medical Genetics and Genomics
Neuroendocrine Secretory Protein 55
Cyclic adenosine monophosphate
Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS. Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. Appl Clin Genet. 2015;8:37–48.
Turan S, Bastepe M. GNAS spectrum of disorders. Curr Osteoporos Rep. 2015;13(3):146–58.
Mariani M, Rigante D, Guerriero C, Ricci F, Sani I, Rossodivita A. Progressive osseous heteroplasia in a 7-year-old girl with osteoma cutis and autoimmune thyroiditis: the importance of investigating GNAS mutations. J Eur Acad Dermatol Venereol. 2016;30(5):905–7.
Ahmed SF, Barr DG, Bonthron DT. GNAS1 mutations and progressive osseous heteroplasia. N Engl J Med. 2002;346(21):1669–71.
Bastepe M. GNAS mutations and heterotopic ossification. Bone. 2018;109:80–5.
Macgregor ME, Whitehead TP. Pseudo-hypoparathyroidism; a description of three cases and a critical appraisal of earlier accounts of the disease. Arch Dis Child. 1954;29(147):398–418.
Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Usardi A, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018;14(8):476–500.
Gelfand IM, Hub RS, Shore EM, Kaplan FS, Dimeglio LA. Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: a case report. Bone. 2007;40(5):1425–8.
Elli FM, Barbieri AM, Bordogna P, Ferrari P, Bufo R, Ferrante E, et al. Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series. Bone. 2013;56(2):276–80.
Han SR, Lee YA, Shin CH, Yang SW, Lim BC, Cho TJ, et al. Clinical and molecular characteristics of GNAS inactivation disorders observed in 18 Korean patients. Exp Clin Endocrinol Diabetes. 2021;129(2):118–25.
Ozaki K, Mituboshi A, Nagai M, Nishiyama A, Nishimura G, Morisada N, et al. Mild progressive osseous heteroplasia overlap syndrome with PTH and TSH resistance appearing during adolescence and not early childhood. Endocrine. 2021;74(3):685–9.
Kaplan FS, Craver R, MacEwen GD, Gannon FH, Finkel G, Hahn G, et al. Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow-up of three previously reported cases. J Bone Joint Surg Am. 1994;76(3):425–36.
Adegbite NS, Xu M, Kaplan FS, Shore EM, Pignolo RJ. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet A. 2008;146a(14):1788–96.
Lebrun M, Richard N, Abeguilé G, David A, CoëslierDieux A, Journel H, et al. Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J Clin Endocrinol Metab. 2010;95(6):3028–38.
Arrigoni P, Minen A. A case of soft tissue ossifications: a case report. JBJS Case Connect. 2019;9(2):e0287.
Aynaci O, MüjganAynaci F, Cobanoğlu U, Alpay K. Progressive osseous heteroplasia. A case report and review of the literature. J Pediatr Orthop B. 2002;11(4):339–42.
Birjandinejad A, Taraz-Jamshidi MH, Hosseinian SH. Total ankylosis of the upper left limb: a case of progressive osseous heteroplasia. Arch Bone Jt Surg. 2016;4(3):285–8.
Chan I, Hamada T, Hardman C, McGrath JA, Child FJ. Progressive osseous heteroplasia resulting from a new mutation in the GNAS1 gene. Clin Exp Dermatol. 2004;29(1):77–80.
Chang G, Li Q, Li N, Li G, Li J, Ding Y, et al. Evaluating the variety of GNAS inactivation disorders and their clinical manifestations in 11 Chinese children. BMC Endocr Disord. 2022;22(1):70.
Demir MK, Toktaş ZO, Akakın A, Yılmaz B, Gürol T, Sarıtaş Y. Progressive osseous heteroplasia and scoliosis. Spine J. 2015;15(12):e19-22.
Eddy MC, Jan DeBeur SM, Yandow SM, McAlister WH, Shore EM, Kaplan FS, et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res. 2000;15(11):2074–83.
Faust RA, Shore EM, Stevens CE, Xu M, Shah S, Phillips CD, et al. Progressive osseous heteroplasia in the face of a child. Am J Med Genet A. 2003;118a(1):71–5.
Goto M, Mabe H, Nishimura G, Katsumata N. Progressive osseous heteroplasia caused by a novel nonsense mutation in the GNAS1 gene. J Pediatr Endocrinol Metab. 2010;23(3):303–9.
Hou JW. Progressive osseous heteroplasia controlled by intravenous administration of pamidronate. Am J Med Genet A. 2006;140(8):910–3.
Justicia-Grande AJ, Gómez-Ríal J, Rivero-Calle I, Pischedda S, Curras-Tuala MJ, Gómez-Carballa A, et al. Case report: two monochorionic twins with a critically different course of progressive osseus heteroplasia. Front Pediatr. 2021;9:662669.
Kumagai K, Motomura K, Egashira M, Tomita M, Suzuki M, Uetani M, et al. A case of progressive osseous heteroplasia: a first case in Japan. Skeletal Radiol. 2008;37(6):563–7.
Lin MH, Numbenjapon N, Germain-Lee EL, Pitukcheewanont P. Progressive osseous heteroplasia, as an isolated entity or overlapping with Albright hereditary osteodystrophy. J Pediatr Endocrinol Metab. 2015;28(7–8):911–8.
Miles O, Cabalag M, McCombe D. Ossification of the superficial radial nerve causing pain: an unusual case of progressive osseous heteroplasia. ANZ J Surg. 2020;90(10):2140–2.
Pereda A, Martos-Tello JM, Garin I, Errea-Dorronsoro J, Perez de Nanclares G. Progressive osseous heteroplasia caused by a mosaic GNAS mutation. Clin Endocrinol (Oxf). 2018;88(6):993–5.
Sahu K, Rout AN, Mohapatra L, Mohanty P. Progressive Osseous heteroplasia: a rare case report. Indian Dermatol Online J. 2020;11(4):604–6.
Santiago F, Vieira R, Cordeiro M, Tellechea O, Figueiredo A. unilateral progressive osseous heteroplasia. Eur J Dermatol. 2009;19(3):214–5.
Schepis C, Lentini M, Calì F. An odd precocious case of progressive osseous heteroplasia. Ital J Dermatol Venerol. 2021;156(3):409–11.
Schimmel RJ, Pasmans SG, Xu M, Stadhouders-Keet SA, Shore EM, Kaplan FS, et al. GNAS-associated disorders of cutaneous ossification: two different clinical presentations. Bone. 2010;46(3):868–72.
Schrander DE, Welting TJ, Caron MM, Schrander JJ, van Rhijn LW, Körver-Keularts I, et al. Endochondral ossification in a case of progressive osseous heteroplasia in a young female child. J Pediatr Orthop B. 2014;23(5):477–84.
Seror R, Job-Deslandre C, Kahan A. Progressive osseous heteroplasia: a rare case of late onset. Rheumatology (Oxford). 2007;46(4):716–7.
Singh GK, Verma V. Progressive osseous heteroplasia in a 10-year-old male child. Indian J Orthop. 2011;45(3):280–2.
Zhang K, Tang H, Zhang R, Wang Y, Su Q, Lin X, et al. Progressive osseous heteroplasia: a case report and literature review. Am J Transl Res. 2021;13(12):14109–14.
Zhang SD, Xie ZL, Zhang KQ, Nh-Tseung K, Zhao JJ. Progressive osseous heteroplasia in a Chinese infant and a novel mutation in the GNAS gene. J Eur Acad Dermatol Venereol. 2018;32(6):e209–11.
El Sobky E, El Sayed SM. Progressive osseous heteroplasia (POH): an Egyptian patient. Egypt J Med Hum Genet. 2010;11(1):79–83.
Kaplan FS, Shore EM. Progressive osseous heteroplasia. J Bone Miner Res. 2000;15(11):2084–94.
Dong H, Zhao X, Cheng H, Mi J. Childhood adiposity, adult adiposity, and bone health. Pediatr Investig. 2021;5(1):6–11.
Cong Q, Liu Y, Zhou T, Zhou Y, Xu R, Cheng C, et al. A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification. Sci Transl Med. 2021;13(599):eabb2233.
We thank the patient and parents for their participation.
This work was funded by the National Key Research and Development Program of China (2021YFC2702005). Beijing Hospitals Authority’s Ascent Plan (DFL20221001), R&D Program of Beijing Municipal Education Commission (KZ202210025030) and Wu Jieping Medical Foundation (320.6750.2022–03-53).
Ethics approval and consent to participate
Not applicable for observational case reports.
Consent for publication
Written informed consent was obtained from the patient’s father for publication of this case presentation and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ma, J., Mo, W., Sun, J. et al. Progressive osseous heteroplasia in a 5-year-old boy with a novel mutation in exon 2 of GNAS: a case presentation and literature review. BMC Musculoskelet Disord 24, 247 (2023). https://doi.org/10.1186/s12891-023-06371-4
- Progressive osseous heteropalasia
- GNAS gene
- Novel mutation
- Heterotopic ossification